Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
1997-02-11
Fleisher, Mindy
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
435 681, 530384, 530413, 530829, C07K 14745, C07K 118, A61K 3836, C12P 2106
Patent
active
056022336
ABSTRACT:
A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.
REFERENCES:
patent: 4285932 (1981-08-01), Smith
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4337244 (1982-06-01), Smith
patent: 4447416 (1984-05-01), Menache-Aronson
patent: 4604285 (1986-08-01), Smith et al.
patent: 4721572 (1988-01-01), Jordan
patent: 4725673 (1988-02-01), Herring
patent: 5071961 (1991-12-01), Kraus et al.
patent: 5120537 (1992-06-01), Esmon et al.
patent: 5153166 (1992-10-01), Jain et al.
patent: 5153175 (1992-10-01), Krueger et al.
patent: 5278144 (1994-01-01), Wolf
patent: 5279956 (1994-01-01), Griffin et al.
Ahmad, et al., "Rapid Purification of Factor IX, Factor X and Prothrombin by Immunoaffinity and Ion Exchange Chromatography," Thrombosis Research (1989) 55:121-133.
Aronson, et al., "Two Forms of the Human Prothrombin Converting Enzyme (Active Factor X) (35769)," Two Forms of X, (1971) 137:4, 1262-1266.
Bajaj, et al., "A Simplified Procedure for Purification of Human Prothrombin, Factor IX and Factor X," Preparative Biochemistry (1981) 11:4, 397-412.
Bauer, et al, "Detection of Factor X Activation in Humans," Blood (1989) 74:6 (Nov. 1), 2007-2015.
Benedict, et al., "Active Site-Blocked Factor Xa Prevents Thrombus Formation in the Coronary Vasculature in Parallel With Inhibition of Extravascular Coagulation in a Canine Thrombosis Model," Blood (1993) 81:8, 2059-2066.
Cassels, et al., "The Interaction of Streptokinase Plasminogen Activator Complex Tissue-Type Plasminogen Activator, Urokinase and their Acylated Derivatives with Fibrin and Cyanogen Bromide Digest of Fibrinogen," Biochem. J. (1987) vol. 247, 395-400.
Chattopadhyay, et al., "Molecular Recognition in the Activation of Human Blood Coagulation Factor X," The Journal of Biological Chemistry, (1989) 264:19, 11035-11043.
Claeson, "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System," Blood Coagulation and Fibrinolysis (1994) 5, 411-436.
Colman, et al., "Section A, Plasma Coagulation Factors," Plasma Coagulation Factors, 3-17.
Crabbe, et al., "Acylated Plasminogen-Streptokinase Activator Complex: A New Approach to Thrombolytic Therapy," Pharmacotherapy (1990) 10:2, 115-126.
Davie, "Chapter 16, The Blood Coagulation Factors: Their cDNAs, Genes, and Expression," Plasma Coagulation Factors, Part 1, Section A, 242-268.
Di Scipio, et al., "Activation of Human Factor X (Stuart Factor) by a Protease from Russell's Viper Venom, Activation of Human Factor X," Biochemistry (1977) 16:24, 5253-5260.
Etingin, et al., "Viral Activation of the Coagulation Cascade: Molecular Interactions at the Surface of Infected Endothelial Cells," Cell (1990) 61:657-662.
Fears, "Development of Anisoylated Plasminogen-Streptokinase Activator Complex from the Acyl Enzyme Concept," Seminars in Thrombosis and Hemostasis (1980) 15:2, 129-139.
Fears, et al., "The Protective Effect of Acylation on the Stability of Anisoylated Plasminogen Streptokinase Activator Complex in Human Plasma," Drugs (1987) 33 (Suppl. 3), 57-63.
Friedberg, et al., "Large Scale Purification of Factor X by Hydrophobic Chromatography," Preparative Biochemistry (1988) 18:3, 303-320.
Furie, et al., "Coagulant Protein of Russell's Viper Venom," Blood Clotting Enzymes, Methods in Enzymology, (1976) 45, 191-205.
Furie, et al., "The Molecular Basis of Blood Coagulation," Cell (1988) 53:505-518.
Gordon, et al., "The Site of Activation of Factor X by Cancer Procoagulant," Blood Coagulation and Fibrinolyses (1991) 2:735-739.
Hoover, et al., "The Adhesive Interaction between Polymorphonuclear Leukocytes and Endothelial Cells in Vitro," Cell (1978) 14:423-428.
Hrinda, et al., "Preclinical Studies of a Monoclonal Antibody-Purified Factor IX, Mononinep.TM." Seminars in Hematology (1991) 28:3, Suppl. 6 (Jul.), 6-14.
Jesty, "Analysis of the Generation and Inhibition of Activated Coagulation Factor X in Pure Systems and in Human Plasma," The Journal of Biological Chemistry (1986) 261:19, 8695-8702.
Kettner, et al, "Synthesis of Peptides of Arginine Chloromethyl Ketone. Selective Inactivation of Human Plasma Kallikrein," Biochemistry, (1978) 17:22, 4778-4783.
Kettner, et al., "The Susceptibilty of Urokinase to Affinity Labeling by Peptides of Arginine Chloromethyl Ketone," Biochimica et Biophysica Acta (1979) 569:31-40.
Kettner, et al., "Active Site Mapping of Human and Rat Urinary Kallikreins by Peptidyl Cholormethyl Ketones," Archives of Biochemistry and Biophysics (1980) 202:2, 420-430.
Kettner, et al., "Inactivation of Trypsin-Like Enzymes with Peptides of Arginine Chloromethyl Ketone," Methods in Enzymology (1981) 80:826-842.
Kettner, et al., "The Selective Affinity Labeling of Factor X.sub.a by Peptides of Arginine Chloromethyl Ketone," Thrombosis Research (1981) 22:645-652.
Kosow, "Purification and Activation of Human Factor X: Cooperative Effect of Ca.sup.++ on the Activation Reaction," Thrombosis Research (1976) 9:565-573.
Lijnen, et al., "Inhibition of Tryspin-Like Serine Proteinases by Tripeptide Arginyl and Lysyl Chloromethylketones," Thrombosis Research (1984) 34:431-437.
Marsh, "Snake Venoms Affecting the Haemostatic Mechanism--a Consideration of their Mechanisms Practical Applications and Biological Significance," Blood Coagulation and Fibrnolysis (1994) 5:399-410.
Mertens, et al., "Pathways in the Activation of Human Coagulation Factor X," Biochem. J. (1980) 185:647-658.
Miletich, et al., "The Synthesis of Sulfated Dextran Beads for Isolation of Human Plasma Coagulation Factors II, IX and X," Analytical Biochemistry, (1980) 105:304-310.
Monahan, et al., "Identification of Human Cohn Fraction III as a Useful Source for the Simultaneous Purification of FIX and FX Zymogens, " Thrombosis Research (1980) 19:743-755.
Nesheim, et al., "The Contribution of Bovine Factor V and Factor Va to the Activity of Prothrombinase," The Journal of Biological Chemistry (1979) 254:21, 10952-10962.
Nesheim, et al., "Cofactor Dependence of Factor Xa Incorporation into the Prothrombinase Complex," The Journal of Biological Chemistry (1981) 256:13, 6537-6540.
Sinha, et al., "Procoagulation Activities of Reversibly Acylated Forms of Factor Xa," Blood, (1995) 86:4153-4157.
Steinberg, et al., "Activation of Factor X", Plasma Coagulation Factors, Part 1, Section A, Chapter 7, 112-119.
Sturzebecker, J., et al., "Acyl-Derivatives of tPA," Thrombosis Research (1987) 47:6, 699-703 (first page missing).
Williams, et al., "Zymogen/Enzyme Discrimination Using Peptide Chloromethyl Ketones," The Journal of Biological Chemistry (1989) 264:13, 7536-7545.
COR Therapeutics Inc.
Degen Nancy J.
Fleisher Mindy
LandOfFree
Process for production of inhibited forms of activated blood fac does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for production of inhibited forms of activated blood fac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for production of inhibited forms of activated blood fac will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-343110